Here are four things to know.
1. Biktarvy is a once-daily, triple-combination tablet used to treat HIV infections.
2. The drug’s wholesale price will be about $36,000 per year, which falls in line with prices of other HIV treatments on the market.
3. Biktarvy contains a boxed warning about exacerbating hepatitis B infections in some patients.
4. ViiV Healthcare filed a lawsuit shortly after Biktarvy’s approval, claiming the drug infringed on patents for its own triple-drug HIV treatment.
More articles on supply chain:
Celgene Executive Chairman Bob Hugin abruptly steps down: 5 things to know
As flu rages throughout Florida, Tamiflu supplies run low
Pfizer’s opioid-filled syringes hit another manufacturing snag: 6 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
